Generics Global Group of Eight (G8) Industry Guide 2017

Description: Generics Global Group of Eight (G8) Industry Guide_2017

Summary

The G8 Generics industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Essential resource for top-line data and analysis covering the G8 generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends and leading companies.

- The G8 countries contributed $189.4 billion in 2016 to the global generics industry, with a compound annual growth rate (CAGR) of 10.9% between 2012 and 2016. The G8 countries are expected to reach a value of $384.0 billion in 2021, with a CAGR of 15.2% over the 2016-21 period.
- Among the G8 nations, the US is the leading country in the generics industry, with market revenues of $99.7 billion in 2016. This was followed by Japan and Germany, with a value of $56.6 and $8.5 billion, respectively.
- Japan is expected to lead the generics industry in the G8 nations with a value of $199.9 billion in 2016, followed by the US and the UK with expected values of $141.2 and $12.1 billion, respectively.

Scope

- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the G8 generics market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the G8 generics market
- Leading company profiles reveal details of key generics market players’ G8 operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the G8 generics market with five year forecasts by both value and volume
- Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country

Reasons to buy

- What was the size of the G8 generics market by value in 2016?
- What will be the size of the G8 generics market in 2021?
- What factors are affecting the strength of competition in the G8 generics market?
- How has the market performed over the last five years?
- Who are the top competitors in the G8 generics market?

Contents:

Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
Group of Eight (G) Generics
Industry Outlook
Generics in Canada
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in France
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Germany
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Italy
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Japan
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Russia
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in The United Kingdom
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in The United States
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading companies

List of Tables
Table 1: G8 generics industry, revenue($bn), 2012
Table 2: G8 generics industry, revenue by country ($bn), 2012
Table 3: G8 generics industry forecast, revenue by country ($bn), 2016
Table 4: Canada generics market value: $ billion, 2012
Table 5: Canada generics market volume: % of total pharma volume, 2012
Table 6: Canada generics market geography segmentation: $ billion,
Table 7: Canada generics market value forecast: $ billion, 2016
Table 8: Canada generics market volume forecast: % of total pharma volume, 2016
Table 9: Canada size of population (million), 2012
Table 10: Canada GDP (constant 2005 prices, $ billion), 2012
Table 11: Canada GDP (current prices, $ billion), 2012
Table 12: Canada inflation, 2012
Table 13: Canada consumer price index (absolute), 2012
Table 14: Canada exchange rate, 2012
Table 15: France generics market value: $ billion, 2012
Table 16: France generics market volume: % of total pharma volume, 2012
Table 17: France generics market geography segmentation: $ billion,
Table 18: France generics market value forecast: $ billion, 2016
Table 19: France generics market volume forecast: % of total pharma volume, 2016
Table 20: France size of population (million), 2012
Table 21: France GDP (constant 2005 prices, $ billion), 2012
Table 22: France GDP (current prices, $ billion), 2012
Table 23: France inflation, 2012
Table 24: France consumer price index (absolute), 2012
Table 25: France exchange rate, 2012
Table 26: Germany generics market value: $ billion, 2012
Table 27: Germany generics market volume: % of total pharma volume, 2012
Table 28: Germany generics market geography segmentation: $ billion,
Table 29: Germany generics market value forecast: $ billion, 2016
Table 30: Germany generics market volume forecast: % of total pharma volume, 2016
Table 31: Germany size of population (million), 2012
Table 32: Germany GDP (constant 2005 prices, $ billion), 2012
Table 33: Germany GDP (current prices, $ billion), 2012
Table 34: Germany inflation, 2012
Table 35: Germany consumer price index (absolute), 2012
Table 36: Germany exchange rate, 2012
Table 37: Italy generics market value: $ billion, 2012
Table 38: Italy generics market volume: % of total pharma volume, 2012
Table 39: Italy generics market geography segmentation: $ billion,
Table 40: Italy generics market value forecast: $ billion, 2016
Table 41: Italy generics market volume forecast: % of total pharma volume, 2016
Table 42: Italy size of population (million), 2012
Table 43: Italy GDP (constant 2005 prices, $ billion), 2012
Table 44: Italy GDP (current prices, $ billion), 2012
Table 45: Italy inflation, 2012
Table 46: Italy consumer price index (absolute), 2012
Table 47: Italy exchange rate, 2012
Table 48: Japan generics market value: $ billion, 2012
Table 49: Japan generics market volume: % of total pharma volume, 2012
Table 50: Japan generics market geography segmentation: $ billion,
Table 51: Japan generics market value forecast: $ billion, 2016
Table 52: Japan generics market volume forecast: % of total pharma volume, 2016
Table 53: Japan size of population (million), 2012
Table 54: Japan GDP (constant 2005 prices, $ billion), 2012
Table 55: Japan GDP (current prices, $ billion), 2012
Table 56: Japan inflation, 2012
Table 57: Japan consumer price index (absolute), 2012
Table 58: Japan exchange rate, 2012
Table 59: Russia generics market value: $ billion, 2012
Table 60: Russia generics market volume: % of total pharma volume, 2012
Table 61: Russia generics market geography segmentation: $ billion,
Table 62: Russia generics market value forecast: $ billion, 2016
Table 63: Russia generics market volume forecast: % of total pharma volume, 2016
Table 64: Russia size of population (million), 2012
Table 65: Russia GDP (constant 2005 prices, $ billion), 2012
Table 66: Russia GDP (current prices, $ billion), 2012
Table 67: Russia inflation, 2012
Table 68: Russia consumer price index (absolute), 2012
Table 69: Russia exchange rate, 2012
Table 70: United Kingdom generics market value: $ billion, 2012
Table 71: United Kingdom generics market volume: % of total pharma volume, 2012
Figure 10: Forces driving competition in the generics market in Canada,
Figure 11: Drivers of buyer power in the generics market in Canada,
Figure 12: Drivers of supplier power in the generics market in Canada,
Figure 13: Factors influencing the likelihood of new entrants in the generics market in Canada,
Figure 14: Factors influencing the threat of substitutes in the generics market in Canada,
Figure 15: Drivers of degree of rivalry in the generics market in Canada,
Figure 16: France generics market value: $ billion, 2012
Figure 17: France generics market volume: % of total pharma volume, 2012
Figure 18: France generics market geography segmentation: % share, by value,
Figure 19: France generics market value forecast: $ billion, 2016
Figure 20: France generics market volume forecast: % of total pharma volume, 2016
Figure 21: Forces driving competition in the generics market in France,
Figure 22: Drivers of buyer power in the generics market in France,
Figure 23: Drivers of supplier power in the generics market in France,
Figure 24: Factors influencing the likelihood of new entrants in the generics market in France,
Figure 25: Factors influencing the threat of substitutes in the generics market in France,
Figure 26: Drivers of degree of rivalry in the generics market in France,
Figure 27: Germany generics market value: $ billion, 2012
Figure 28: Germany generics market volume: % of total pharma volume, 2012
Figure 29: Germany generics market geography segmentation: % share, by value,
Figure 30: Germany generics market value forecast: $ billion, 2016
Figure 31: Germany generics market volume forecast: % of total pharma volume, 2016
Figure 32: Forces driving competition in the generics market in Germany,
Figure 33: Drivers of buyer power in the generics market in Germany,
Figure 34: Drivers of supplier power in the generics market in Germany,
Figure 35: Factors influencing the likelihood of new entrants in the generics market in Germany,
Figure 36: Factors influencing the threat of substitutes in the generics market in Germany,
Figure 37: Drivers of degree of rivalry in the generics market in Germany,
Figure 38: Italy generics market value: $ billion, 2012
Figure 39: Italy generics market volume: % of total pharma volume, 2012
Figure 40: Italy generics market geography segmentation: % share, by value,
Figure 41: Italy generics market value forecast: $ billion, 2016
Figure 42: Italy generics market volume forecast: % of total pharma volume, 2016
Figure 43: Forces driving competition in the generics market in Italy,
Figure 44: Drivers of buyer power in the generics market in Italy,
Figure 45: Drivers of supplier power in the generics market in Italy,
Figure 46: Factors influencing the likelihood of new entrants in the generics market in Italy,
Figure 47: Factors influencing the threat of substitutes in the generics market in Italy,
Figure 48: Drivers of degree of rivalry in the generics market in Italy,
Figure 49: Japan generics market value: $ billion, 2012
Figure 50: Japan generics market volume: % of total pharma volume, 2012
Figure 51: Japan generics market geography segmentation: % share, by value,
Figure 52: Japan generics market value forecast: $ billion, 2016
Figure 53: Japan generics market volume forecast: % of total pharma volume, 2016
Figure 54: Forces driving competition in the generics market in Japan,
Figure 55: Drivers of buyer power in the generics market in Japan,
Figure 56: Drivers of supplier power in the generics market in Japan,
Figure 57: Factors influencing the likelihood of new entrants in the generics market in Japan,
Figure 58: Factors influencing the threat of substitutes in the generics market in Japan,
Figure 59: Drivers of degree of rivalry in the generics market in Japan,
Figure 60: Russia generics market value: $ billion, 2012
Figure 61: Russia generics market volume: % of total pharma volume, 2012
Figure 62: Russia generics market geography segmentation: % share, by value,
Figure 63: Russia generics market value forecast: $ billion, 2016
Figure 64: Russia generics market volume forecast: % of total pharma volume, 2016
Figure 65: Forces driving competition in the generics market in Russia,
Figure 66: Drivers of buyer power in the generics market in Russia,
Figure 67: Drivers of supplier power in the generics market in Russia,
Figure 68: Factors influencing the likelihood of new entrants in the generics market in Russia,
Figure 69: Factors influencing the threat of substitutes in the generics market in Russia,
Figure 70: Drivers of degree of rivalry in the generics market in Russia,
Figure 71: United Kingdom generics market value: $ billion, 2012
Figure 72: United Kingdom generics market volume: % of total pharma volume, 2012
Figure 73: United Kingdom generics market geography segmentation: % share, by value,
Figure 74: United Kingdom generics market value forecast: $ billion, 2016
Figure 75: United Kingdom generics market volume forecast: % of total pharma volume, 2016
Figure 76: Forces driving competition in the generics market in the United Kingdom,
Figure 77: Drivers of buyer power in the generics market in the United Kingdom,
Figure 78: Drivers of supplier power in the generics market in the United Kingdom,
Figure 79: Factors influencing the likelihood of new entrants in the generics market in the United Kingdom,
Figure 80: Factors influencing the threat of substitutes in the generics market in the United Kingdom,
Figure 81: Drives of degree of rivalry in the generics market in the United Kingdom,
Figure 82: United States generics market value: $ billion, 2012
Figure 83: United States generics market volume: % of total pharma volume, 2012
Figure 84: United States generics market geography segmentation: % share, by value,
Figure 85: United States generics market value forecast: $ billion, 2016
Figure 86: United States generics market volume forecast: % of total pharma volume, 2016
Figure 87: Forces driving competition in the generics market in the United States,
Figure 88: Drives of buyer power in the generics market in the United States,
Figure 89: Drives of supplier power in the generics market in the United States,
Figure 90: Factors influencing the likelihood of new entrants in the generics market in the United States,
Figure 91: Factors influencing the threat of substitutes in the generics market in the United States,
Figure 92: Drives of degree of rivalry in the generics market in the United States,
Figure 93: Mylan Inc.: revenues & profitability
Figure 94: Mylan Inc.: assets & liabilities
Figure 95: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 96: Teva Pharmaceutical Industries Limited: assets & liabilities
Figure 97: STADA Arzneimittel AG: revenues & profitability
Figure 98: STADA Arzneimittel AG: assets & liabilities
Figure 99: Sanofi SA: revenues & profitability
Figure 100: Sanofi SA: assets & liabilities
Figure 101: Daiichi Sankyo Co., Ltd.: revenues & profitability
Figure 102: Daiichi Sankyo Co., Ltd.: assets & liabilities
Figure 103: Sawai Pharmaceutical Co., Ltd.: revenues & profitability
Figure 104: Sawai Pharmaceutical Co., Ltd.: assets & liabilities
Figure 105: Abbott Laboratories: revenues & profitability
Figure 106: Abbott Laboratories: assets & liabilities
Figure 107: Krka, d. d., Novo mesto: revenues & profitability
Figure 108: Krka, d. d., Novo mesto: assets & liabilities

Ordering: Order Online - http://www.researchandmarkets.com/reports/4176244/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Generics Global Group of Eight (G8) Industry Guide 2017
Web Address: http://www.researchandmarkets.com/reports/4176244/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

Quantity
Electronic (PDF) - Single User: USD 1495
Electronic (PDF) - Site License: USD 2990
Electronic (PDF) - Enterprisewide: USD 4485

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card:

You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer:

Please transfer funds to:

- Account number 833 130 83
- Sort code 98-53-30
- Swift code ULSBIE2D
- IBAN number IE78ULSB98533083313083
- Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp